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Abstract
Introduction: Diabetic Foot Ulcers (DFUs) are one of the more dangerous complications of diabetes, contributing to morbidity, 
mortality, and major financial strain, potentially affecting patients’ quality of life. Therefore, an effective DFU treatment is needed 
to both heal and reduce severe consequences, such as amputation. Studies into effective multiple therapeutic interventions for 
DFUs indicate that Hyperbaric Oxygen Therapy (HBOT) may be a current alternative for treating patients presenting with DFUs.
Here, we seek to determine whether HBOT is clinically effective in wound healing of DFUs and reducing associated high 
amputation levels. Further, it examines whether HBOT is a safe therapy for treating diabetes patients with foot ulcers.
Methods: A comprehensive search strategy was applied to eight databases (CINAHL, Medline, EMBAS, PsycINFO, Joanna 
Brigg’s Institute (JBI), Ovid, Cochrane Library and PubMed) to obtain relevant Randomised Controlled Trials (RCTs). Stringent 
pre-defined inclusion and exclusion criteria were applied regarding eligibility of the retrieved studies. A manual search of the 
references contained in these studies was performed alongside a search of e-libraries and medical websites. Eight RCTs were 
included, shown in a PRISMA flow diagram; data were extracted using the JBI’s data extraction tool before being critically 
appraised using the JBI critical appraisal tool. Findings were then summarised and interpreted using narrative synthesis.
Results: Three main themes emerged from the included studies: the effect of HBOT on ulcer healing, its effect on amputation 
rate, and HBOT safety (i.e., concerns about adverse events and oxidative stress). Most studies concluded that HBOT assists in 
size reduction and accelerates healing of DFUs. 
Conclusion: HBOT is an effective, safe treatment, as an additional therapy for standard wound care, for DFUs in the short term, 
if at least 20 sessions are completed. HBOT reduces the risk for severe consequences, not the consequences per se, i.e. infection. 
Further rigorous examination by larger, well-designed RCTs is required to investigate the relative efficacy and cost-effectiveness 
of HBOT.
Introduction
The advent of diabetes has been documented regionally and 
globally by the International Diabetes Federation since 2000, as 
diabetes was estimated the fifth major cause of death [1]. Diabetes 
affects 25% of those 65 years and older, while half of those below 
65 suffer from pre-diabetes [2]. Prevalence of both types gradually 
rose until 2017, when 4 million people worldwide had died from 
diabetes [3]. By 2019, the number of cases stood at 463 million, 
with 578 cases predicted for 2030, and 700 million for 2045 [4]. 
The lifetime risk of foot ulcers was estimated at 25% for 
diabetes patients [5]. Epidemiologically, global Diabetic Foot 
Ulcers (DFU) prevalence was roughly 6.3% higher in males 
(4.5%) than females (3.5%), and higher in T2DM patients at 
6.4% and 5.5% in T1DM [6]. Physical, psychological, and 
productive consequences reducing patients’ quality of life make 
ulcers an alarming risk [7]. In the US, DFU care costs Medicare 
approximately $25 billion in 2008 [8]. Around £662 million was 
spent by the UK National Health Services (NHS) on managing 
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DFUs in 2012 [9]. More worryingly, DFUs have been closely 
associated with an elevated risk of mortality. According to [8], 
10.7% of DFU patients died in 2008 in the American Medicare 
community. In terms of physical complications, 85% of DFUs 
caused lower limb amputations [10].
The greatest consequence of DFU is foot amputation, 
equating to medical and financial burdens. [11-13] reported that 
75% of DFU-related amputations are the major global source of 
non-trauma amputations, which increase hospital admissions [14] 
and deaths [15]. 
Hyperbaric Oxygen Therapy (HBOT) is an inhalation 
and diffusion therapy using high-dose and short-term oxygen, 
administrated systemically via patient blood circulation and 
airways [16] with devices pressurised with air up to 2 to 2.5 
atmospheres (ATA) and patients breathe 100% oxygen [17]. 
HBOT can enhance oxygen in hypoxic tissues, decrease oedema, 
generate collagen, encourage perfusion, and reduce inflammatory 
cytokines [18]. 
Pathophysiology of DFUs
Hyperglycaemia is a biochemical aberration inhibiting 
endothelial nitric oxide synthase production and activation, and 
interaction of protein with sugar (Millard reaction), leading to 
accelerated development of neuropathy and vascular changes [19]. 
The main factors which affect the underlying pathophysiology of 
foot ulcers include peripheral neuropathy, ischemia from vascular 
diseases, inflammatory cytokines and susceptibility to infection 
[20]. 
Neuropathy is accountable for over 60% of DFUs [20], 
where the metabolic disorders caused by hyperglycaemia 
precipitate neuropathy in patients [21]. The polyol path is among 
the most prevalent disorders [22], in which intracellular glucose is 
converted into sorbitol and fructose as a consequence of increased 
activity of aldose reductase and sorbitol dehydrogenase enzymes 
[23]. The risk of accumulating sugar products lies in the decrease 
of nerve cell myoinositol synthesis necessary for normal neuron 
conduction [24]. Conversion of chemical glucose leads to depletion 
of phosphate stock of nicotinamide adenine dinucleotide, vital for 
detoxifying Reactive Oxygen Species (ROS) and synthesising 
vasodilator Nitric Oxide (NO) [19]. Consequently, oxidative 
pressure inside the neuron and vasoconstriction are increased, 
causing ischemia, which contributes to cell damage, abnormal 
activation of protein kinase C, and nerve death [25].
Neuropathy impacts motor, autonomic and sensory 
components of the nervous system in diabetes patients [20]. 
With regards to the motor aspect, the damage to the affected 
foot’s intrinsic muscles contributes to a disturbance between its 
flexion and extension [26]. Deformities (i.e., bony prominence and 
pressure points) arise in the anatomy of the foot, which then lead 
to skin breakdown and ulceration [27]. The autonomic nervous 
system is adversely influenced by the neuropathy by disrupting 
the oily and sweat gland functions, thus, the foot lacks its natural 
skin moisturising ability and becomes drier and thus more prone 
to infection [28]. As neuropathy weakens sensation in the affected 
limb, patients do not notice the wounds to which they are exposed 
and continue to put pressure on them, thus, exacerbating these 
ulcers [29].
Peripheral Artery Disease (PAD), which accounts for 
approximately 50% of patients presenting with diabetic foot, 
affects the tibial and peroneal arteries of the calf (gastrocnemius 
muscle) [30]. In addition, persistent hyperglycaemia often triggers 
smooth cell defects and endothelial cell impairment of the 
peripheral arteries [21]. As a result, vasodilators produced from 
the endothelium diminish and cause constriction. Further, the rise 
in thromboxane A2, a vasoconstrictor and platelet aggregation 
agonist, is also linked to hyperglycaemia in diabetes, which 
contributes to elevated plasma hypercoagulability risks [31]. The 
vascular extracellular matrix may also be subject to changes in 
arterial lumen stenosis [19]. These responses may interfere with 
other factors common to diabetes patients, such as hypertension 
and hyperlipidaemia, causing occlusive artery disease that 
ultimately leads to lower extremity ischemia and increased risk of 
DFUs [32].
Here, we seek to determine whether HBOT is clinically 
effective in wound healing of DFUs and reducing associated high 
amputation levels. Further, it examines whether HBOT is a safe 
therapy for treating diabetes patients with foot ulcers.
Methodology
Search Strategy
A three-step search strategy was applied and aimed at 
identifying all eligible published studies. First, CINAHL, Medline, 
EMBAS, PsycINFO, JBI, Ovid, Cochrane Library, and Pubmed 
were searched by one of the research team. An initial limited 
search was first undertaken to identify articles on the topic. The 
text words contained in the titles and abstracts of relevant articles, 
and the index terms used to describe the articles were then used to 
develop a full search strategy for the report. The search strategy, 
including all identified keywords and index terms, were adapted 
for each included information source. Initial keywords used in this 
review were: Adult diabetes AND/OR Diabetic foot ulcers patients 
AND/OR Diabetic patients; Hyperbaric oxygen therapy AND/OR 
Hyperbaric Oxygenation AND/OR Hyperbaric oxygen chamber 
AND/OR Hyperbaric AND/OR HBOT safety AND/OR HBOT 
effectiveness AND/OR Ulcers healing AND/OR Ulcers treatment 
AND/OR Adverse effects AND/OR Complications. Second, a 
process of screening, supplementary search parameters were 
used to ensure relevance to the topic, duplicate articles and those 
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not relevant were removed (n=1936). Following abstract review, studies were excluded if they were not primary research, unrelated, 
excluded human participants, non-English language and did not have full text availability for the review. 
Finally, the full text of selected citations was assessed in detail against the inclusion criteria by two independent reviewers. 
Reasons for exclusion of full text studies that did not meet the inclusion criteria was recorded and reported in the systematic review. 
Disagreements between the reviewers at each stage of the study selection process were all resolved through discussion, and by including 
a third reviewer if required. The results of the search were reported in full in the final systematic review and presented in a Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram [33]. Of the 2,022 papers generated using the 
keywords, a final 8 papers were included for analysis. The PICOS tool focused on the Population, Intervention, Comparison, Outcomes 
and Study (PICOS) type to identify suitable primary research studies to be included.
Critical appraisal tools such as CASP and JBI, were utilised to thoroughly examine the relevant primary studies to verify the 
probability of errors and biases in the design and reliability of findings, which ultimately serve as the bases for assessing study quality 
[34,35]. The JBI data extraction tool for experimental/observation studies was used in this study. Data was subsequently tabulated and 
designed according to JBI tool items, to facilitate the writer’s data handling synthesis and results’ reporting stages. The eight included 
studies were evaluated using the new JBI-MAStARI critical appraisal tool and ranged between high and moderate.
Figure 1: PRISMA Flow Diagram indicating included studies (adapted from [33]).
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Results
Characteristics of the Included Studies
The participants in the eight studies totalled 609, with [16] having the highest sample size (n=164), and [36] having the smallest one 
(n=30). All trials identified the participants’ age group to be 18 years or above. Diabetes patients who had DFUs that had remained for more 
than four weeks were the united criterion used in these studies. The study by [36] is exceptionally confined only to participants who have 
non-ischemic DFUs. 
The classification of these DFUs on Wagner’s scale was nevertheless slightly different across the studies. To further explain that point, 
three of the trials selected patients with 3rd grade ulcers or less [37-39], while four extended further to involve 4th grade DFU patients as well 
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95 min), five 
days a week for 
eight weeks (40 
treatment ses-
sions).
* Effect on ulcer healing
Complete healing of the index ul-
cer was achieved in 37 patients at 
1-year of follow-up: 25/48 (52%) 
in the TG and 
12/42 (29%) in the CG (P 0.03).
*Effects on amputation
3 major amputations were per- 
formed in the TG as compared 
with 1 in the CG within the 1st 
year.
*The frequency of adverse 
events was low 
In TG: 1 fatal outcome, 2 post-
session hypoglycaemia, 1 endured 
post-traumatic otitis, 2 my- ringot-
omy needed with tube placement, 
1 HBOT session-related dizziness, 
1 worsening of cataracts 
In CG: 1 post-session hospitalisa-
tion due to losing consciousness, 
4 post-session hypoglycemia, 2 
my- ringotomy needed with tube 
placement, 1 minor head injury 
after fall inside the hyperbaric 
chamber in CG.
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were given to 
participants as 
5 days per week 
for 6 weeks (30 
sessions), each 
session takes 90 
min of HBOT 
(breathing 
oxygen at 244 
kPa) or sham 
(breathing air at 
125 kPa).
Patients were 
followed for 6 
weeks after the 
end of hyper-
baric sessions 
and returned to 
the clinic every 
week for wound 
assessment and 
treatment.
*Meeting Criteria of Need for 
Amputation or Undergoing 
Amputation
Criteria for major amputation 
were met in 13 of 54 patients in 
the CG and 11 of 49 in the TG 
(odds ratio 0.91 [95% CI 0.37, 
2.28], P = 0.846).
The percentage of amputations 
recommended of any type (major 
or minor) was 51% in TG and 
48% in CG (1.12 [0.52, 2.43], P 
= 0.771). 
Beyond the adjudicated indica-
tion for amputations, only 1 actual 
amputation occurred during the 
12-week study period, and this 
was the removal of a toe in CG.
10 of the 11 participants who 
received HBOT treatment and met 
the criteria for major amputation 
were recommended to have a 
below-knee amputation, and all 
of those assessed to require major 
amputation in CG (n = 13) were 
recommended to have below-knee 
amputation. 14 (28.6%) and 13 
(24.1%) participants were adjudi-
cated to undergo minor amputa-
tions in TG and CG, respectively 
(1.26 [0.52, 3.04], P = 0.605).
*Wounds healing
Twelve (22%) patients in the CG 
and 10 (20%) in the TG were 
healed (0.90 [0.35, 2.31], P = 
0.823). All other indices of wound 
healing were also not statistically 
significantly different between 
groups. 
*Adverse events
In TG: 1 an episode of CHF, 9 
cases of inability to equalise mid-
dle ear pressure during treatment, 
4 hypoglycaemic episode.
In CG: 3 cases of inability to 
equalise middle ear pressure dur-
ing treatment, 2 hypoglycaemic 
episode. 
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for 90 minutes at 
2.5 atmospheres 
absolute (ATA) 
5 days a week 
for 2 weeks.
*Effects on Ulcers healing 
TcPo2 in the HBO group increased 
on day 7 (477.8 ± 118.2 mm Hg 
versus 37.06 ± 5.23 mm Hg, P 
<0.01) and day 14 (501.1 ± 137.7 
mm Hg versus 35.61 ± 4.85 mm 
Hg, P <0.01). 
Ulcer size reduction in the HBO 
group was greater than that of the 
control group (42.4% ± 20.0% 
versus 18.1% ± 6.5%, P <0.05). 
*Effects on oxidative stress
MDA levels, SOD, and CAT were 
all significantly higher in the HBO 
than in the control group on day 
14 (P<0.05).
*Adverse events
No serious complications such as 
death or amputation or other ad-
verse reactions such as barotrau-
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pressure for 120 
minutes; for 5 
days a week for 
4 consecutive 
weeks.
*Effects on ulcers healing
Complete DFU closure was 
achieved in 5 patients (25%) in 
the HBOT group (n = 20) versus 
1 participant (5.5%) in the routine 
care group (n = 18) (P = .001). 
The HBOT group showed statisti-
cally significant improvements in 
inflammation index, blood flow, 
and health-related quality of life 
from pretreatment to 2 weeks after 
the last therapy ended (P < .05). 
Hemoglobin A1c was significantly 
lower in the HBOT group follow-
ing treatment (P < .05) but not in 
the routine care group.
*Effects on amputation rate
The AR was 5% for the HBOT 
group and 11% for the routine 
care group (χ2= 15.204, P = .010).
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daily for 5 days 
a week with 2 
days off, for a 
total number of 
20 to 40 sessions 
according to the 
ulcer response. 
The session 
began with a 
gradual pressure 
increase to the 
designated treat-
ment pressure of 
approximately 
2.5 ATA over 
about 10 to 15 







lasted for 1 hour. 
Then, gradual 
decompression 
over about 10 to 
15 minutes was 
made.
*Effects on ulcers healing
A significantly greater percentage 
of HBOT-treated wounds (33.3%, 
5/15) achieved complete closure 
than conventional therapy–treated 
wounds (0%, 0/15; P = .014) 
at the end of treatment. This 
significant difference was main-
tained throughout the 8 weeks of 
follow-up. At the end of all HBOT 
sessions and 2 months of conven-
tional treatment, the median ulcer 
surface area was significantly 
reduced in TG but not in CG. 
This significant ulcer size reduc-
tion in TG was maintained at 4 
and 8 weeks of follow-up.
Complete healing of the target 
ulcer, at the end of the treatment, 
was observed in 5 cases in TG 
versus no case in the CG, P = 
.014*. At 4 and 8 weeks of follow-
up, these numbers were increased 
to 7 and 10 cases versus 2 and 3 
cases in TG versus the CG p, P = 
.046*, .025*, respectively.
On bivariate analysis, it was found 
that a significantly higher wound 
healing rate was associated with 
more HBOT sessions completed (r 
= 0.888, P = .0001, 95% confi-
dence interval = 0.6904-0.9626).]
*Adverse events
Complications frequency was 
non-significantly different be-
tween both groups. 
[Mild to moderate wound infec-
tions were observed in 3 (20%) 
versus 5 (33.3%) cases of TG 
versus CG, respectively, during 
the period of treatment. This was 
cleared after surgical debridement, 




There was no major amputation 
in both groups while minor (toes) 
amputations were done to one 
patient in each group. 
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FiO2 except for 
three blocks of 
5 min during 
which ambi- 
ent air was 
administered to 
prevent oxy- gen 
intoxication. 
HBOT was 
scheduled for 5 
days per week 
until a maximum 
of 40 sessions 




* Effects on Limb salvage
Limb salvage was achieved in 47 
patients in the CG vs. 53 patients 
in the TG (risk difference, 10% 
[95% CI24to23]). 
* Effects on Wound healing
After 12months, 28 index wounds 
were healed in the CG vs. 30 in 
the TG (RD 3% [95% CI 214 to 
21]).
No statistically significant dif-
ference was found in the time 
to complete ulcer healing of the 
index ulcer between both groups. 
* Effects on Amputation
- Freedom From Any Amputation 
of the Index Limb. 31 patients 
(52%) in the CG remained free of 
any amputation (i.e., including mi- 
nor amputations), compared with 
38 (63%) patients in the TG group 
(RD 12% [95% CI 26to 28]).
- Amputation-Free Survival
 AFS was achieved in 41 patients 
in the CG and 49 patients in the 
TG (RD 13% [95% CI 22 to 28]).
*Adverse Events and Mortality 
A total of 14 participants died dur-
ing the follow-up period (9 [15%] 
in the CG vs. 5 [8%] in the TG; 
RD 7% [95% CI 25 to 19]). 
2 serious adverse events occurred 
that were attributable to HBOT: 
an oxygen- induced seizure and 
barotraumatic perforation of 
the tympanicmembrane. Both 
recovered without lasting conse-
quences. 
3 cases had required preventive 
myringotomy with tube placement 
due to the inability to equalise the 
pressure of the middle ear during 
HBOT.
Citation: Alshmimry AH, Jiwani SI, Gyasi-Antwi P, Adams GG (2021) Effectiveness and Safety of Hyperbaric Oxygen Therapy (HBOT) in Treating Diabetic Foot Ulcers 
(DFUs). Curr Res Clin Diab Obes 1: 103. DOI: 10.29011/CRCDO-103.100003














foot or ankle 
ulcer (Grade 
1 or 2 or 3 
on Wanger 
system) for 













five days a week 
in mono- place 
chamber. (20- 30 
treatment ses-
sions). A session 
consisted of 
a duration of 
compression in 





for 85 mins, and 
then a 5 mins 
decompression 
period.
* Effects on inflammatory mark-
ers
Reduction of WCC and CRP in 
TG were significant through-
out the treatment (p=0.046 and 
p=0.039, respectively). 
* Effects on ulcers healing
With the treatment, reduction in 
size of the ulcer was observed in 
both groups, and it was significant 
(p<0.001) in TG. Using Pairwise 
comparison, wound reduction in 
every ten days of measurement 
was significant (p<0.001) in TG 
compared to the CG.
A total of 26 patients (86.7%) 
from the TG achieved complete 
ulcer healing at six months’ fol-
low-up, while 18 patients (60%) 
in CG’s ulcer healed completely.
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* Effects on wound healing
The means of wound size over 
time points (Day 0, 10, 20 and 30) 
among patients under TG were 
statistically significantly differ-
ent [F(1,61)=30.86, p<0.001)] 
compared to CG. 
Multiple logistic regression analy-
sis showed that TG has nearly 44 
times higher odds to achieve at 
least 30% wound size reduction 
within the study period (95%CI: 
7.18, 268.97, p<0.001).
Table 1: Characteristic of Included Studies.
Intervention/Comparator Characteristics
In six of the included trials, a standard diabetic foot treatment 
in conjunction with HBOT was compared with standard care 
alone. In the studies by [16] and [40], the intervention was HBOT, 
while the placebo/sham air was the comparator. With respect 
to the types of HBOT chambers, half of the experiments were 
performed in single-seater chambers and the remaining half in 
multi-person chambers. The HBOT session varied between 60 and 
120 min throughout the studies. The frequency of intervention was 
given as a daily session five days a week. A different intervention 
dosage (twice a day) was given by [37]. The average length of 
the intervention across the eight trials was 20 to 40 sessions. 
The follow-up phase was completed in five of the eight studies 
[16,36,39-41].
Outcomes Characteristics
The eight studies mainly measured the effectiveness of the 
intervention on ulcer healing, which is the primary outcome of this 
review. As a secondary outcome, five studies measured the effect 
of HBOT on the amputation rate. Another secondary outcome 
was the intervention safety and its subsequent adverse events, 
as reported by the five studies. In addition, [37] was unique in 
examining oxidative stress as a side effect of HBOT. 
Results and Discussion
Theme 1: Effect of HBOT on Ulcer Healing
The most clinically important theme was the effectiveness of 
HBOT on ulcer healing, which was measured by all of the included 
studies. Six of the eight studies noted the beneficial effects of 
HBOT for accelerating healing and reducing the size of DFUs 
[16,36-39,42]. Most studies supporting HBOT’s effectiveness 
have a quality score of 8 to 13 on JBI, thereby rendering their 
findings trustworthy. Interestingly, in all six studies, the favourable 
effect was conditional on the administration of HBOT as an adjunct 
therapy to the standard care for DFUs. This result can be explained 
by the fact that the treatment of DFUs is complex and requires 
an integrated approach to achieve the desired healing. This is 
precisely what previously led the Society for Vascular Surgery to 
choose a range of adjunctive interventions—including HBOT—to 
investigate their efficacy [43]. The application of our review results 
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indicates that HBOT should be administered supplementary to 
standard DFU care. This finding is consistent with the results of a 
previous prospective randomised investigation conducted by [44], 
who lauded the efficacy of HBOT as a concomitant therapy with 
standard care for improving the healing of DFUs. The outcome 
of our review is also supported by the findings of a previous SR 
[43], who investigated the best available evidence supporting the 
use of different adjuvant therapies for DFUs. They concluded 
that HBOT was superior to other interventions for accelerating 
DFU wound healing. Despite their large final sample (n=1526), 
the restricted quality (low to medium) of the included studies 
weakens the reliability of their review findings. Our outcome is 
also in agreement with a more recent study, by [45], whose meta-
analysis yielded findings confirming the helpful impact of HBOT 
on the promotion of DFU healing. However, their small sample 
size (n=585) demands caution when using this result.
In relation to discovering the circumstances in which HBOT 
was useful in treating ulcers, the six supported studies revealed 
near-consistent results regarding intervention characteristics. In 
brief, the studies combined resulted in a session lasting between 60 
and 120 minutes, administered 5 times weekly for 6–8 weeks (20–
40 sessions). Only three of the six studies addressed the follow-
up duration [16,36,39]. These data did not reveal any confirmed 
correlations between the circumstances of HBOT intervention and 
its beneficial effect on ulcer healing, since the oppositional studies 
had the same HBOT characteristics. It should be noted that the six 
studies have advocated that a minimum of 20 sessions should be 
conducted to gain this benefit of HBOT. However, in [38], HBOT 
was conducted twice weekly, resulting in a study period limited 
to only two weeks. This can be attributed to that study’s intention 
of testing an HBOT-associated oxidative stress risk hypothesis, 
which resulted in the intervention dosage being doubled to avoid 
prolonging the overall intervention time, thereby reducing the 
possibility of this risk in the treatment group. This exceptional 
finding supports the need for future studies that emphasise the 
link between short-and-long-term HBOT efficacy in ulcer healing, 
taking into account other factors such as oxidative stress and 
inflammatory markers. In terms of inflammatory markers, [39] 
study was unique in evaluating the effect of HBOT on WBCs and 
CRP, and they concluded that there was a significant reduction 
in their levels in the HBOT group. This result reflects what had 
previously been known about the physiological effect of HBOT in 
providing an anti-inflammatory effect that reduces inflammatory 
biomarkers and enhances the immune response [46]. 
The characteristics of patients who would potentially 
benefit from HBOT remain controversial. The frequent criteria for 
response to HBOT was having a chronic DFU (more than 4 weeks) 
and a grade 4 or less on the Wagner Ulcer Classification System. 
The beneficiaries in one study [36] were patients with chronic non-
ischemic DFUs. It is hard to determine if there is a correlation 
between this patient category and the efficacy of HBOT based on 
this single inclusion of non-ischemic ulcers.
In contrast to the above, two studies [40] and [41] repudiated 
the efficacy of HBOT, finding no differentiation in ulcer healing 
between their HBOT and standard wound care groups. However, in 
addition to the large sample sizes (n=103 and n=120, respectively), 
the high JBI scores of these studies (13 and 10, respectively) 
implies that their findings should not be underestimated. In 
addition, the studies used follow-up periods of 6 weeks and 12 
months, respectively. In [40], there was a 2% greater healing rate 
in the control group compared to the treatment group; this could 
have been caused by the unequal sample populations in the two 
study groups (CC:54; TG:49). Another important discovery was 
the inclusion of patients with ischemic DFUs only [41]. Their 
results found no additional benefit to using HBOT for achieving 
significant improvement of ulcer healing. With this in mind, it 
could conceivably be suggested that this finding indicates HBOT 
may not be beneficial for DFU patients with severe ischemia, 
which had previously been noted in the review findings of [43]. 
This could be attributed to the assumption that, in a state of 
sufficient tension, oxygen cannot reach ischemic areas to induce 
angiogenesis, so it is doubtful that HBOT would be effective in 
cases of severe ischemia. 
Our review highlights the need for further research to 
investigate the types of DFUs likely to respond to HBOT. 
Notwithstanding these observations, the outcomes of both studies 
were consistent with the SR [47], who concluded that there was no 
difference in ulcer healing rates between HBOT and conventional 
wound treatment. What strengthens the reliability of their results 
is the methodological quality of the studies used in the review. 
Their meta-analysis found, however, that HBOT was superior to 
conventional treatment for reducing the size of an ulcer wound. 
One of the main issues that emerged from the finding that HBOT 
effectiveness is similar to standard care is the need to examine 
the HBOT’s cost-effectiveness, such that a complete profile of its 
efficacy can be provided, which will then help clinicians to make 
decisions about using or dispensing with the practice.
Theme 2: Effect of HBOT on Amputation Rates
The second theme identified in this review was that the 
effect of HBOT on amputation rates, since five of the eight 
included studies reported it as a secondary endpoint. Most studies 
agreed that HBOT provides no benefit in reducing amputation 
rates [36,40,41], although [38] confirmed HBOT’s advantage in 
reducing the risk of amputation. Interestingly, [16] observed that 
HBOT was correlated with a high incidence of major amputations 
(three cases) and a similar rate of minor amputations (four cases). 
This may be attributed to lower blood pressure levels in the toe 
(15 mm Hg) observed in their study’s amputees, indicating a 
poor perfusion status. Patients with DFUs and peripheral arterial 
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occlusive disease typically have poor conditions that exacerbate 
clinical consequences, including amputations. An evidence for that 
multi-centre trial [41], which primarily included patients with limb 
ischemia and HBOT, also found no improvements in amputation 
rates. 
It is challenging to understand the discrepancy of this theme’s 
outcomes; they may be due to the lack of differentiation between 
ischemic and non-ischemic patients in most of the studies. Our 
findings are compatible with [48], which included only ischemic 
ulcer patients and found no impact of HBOT on amputation rates. 
[49] also found no effect on amputation rates when studying 
patients with non-ischemic DFUs. This finding was replicated in 
[47], which found no changes in major and minor amputation rates 
between HBOT and standard care.
The variations in amputation indications adopted by the 
studies is another possible explanation for the diverse findings of 
this theme. For example, the amputation indications that triggered 
major amputations in [16] were life-threatening infection and 
refractory pain. This finding challenges the amputations to be 
undertaken in this study as their amputation indications are 
underestimated and limited to infection. The study for amputation 
indicated [40]: persistent deep infections involving bones and 
tendons, pain that impedes movement, no significant progress in 
wound healing during the follow-up period and the inability to 
bear weight on the affected limb. Notwithstanding the drawback 
of not conducting actual amputations on the basis of the findings of 
the study, their use of a blinded-expert vascular surgeon minimised 
the risk of bias associated with amputation decisions.
[44] confirmed the beneficial impact of HBOT for minimising 
major and minor amputations. More recently, [45] concluded that 
the requirements for a major amputation have been lowered by 
HBOT, roughly by half. One possible reason for [38] finding 
could be the inclusion of patients with Grade 3 DFUs and lower. 
To clarify, the lower the degree of the ulcer, the lower the risk 
of amputation associated with it. [50] projected the amputation 
rate at 2% for patients with Grade 1 and 2 DFUs, 30% for Grade 
3 and 52% for Grade 4. In response, [16] argued that, regardless 
of the effect of the therapy, patients with Grade 4 ulcers face an 
unavoidable risk of amputation. This could indicate a negative 
correlation between the ulcer grade and the potential effect of 
HBOT on amputation rates; however, the absence of a follow-up 
period and restriction of the study to a single centre challenged the 
reliability of [38] findings.
Theme 3: HBOT Safety (Adverse Events and Oxidative Stress)
In five of the studies, HBOT Safety was reported 
[16,36,37,40,41]. The findings did not indicate any significant 
differences in the incidence of adverse effects between HBOT 
and standard treatment. In addition, the frequency of these HBOT-
related harmful effects reported in the studies was low. This 
finding is consistent with that observed in [51], who concluded 
that adverse events associated with HBOT were infrequent and 
reversible and were not distinct from those that occurred in the 
control group. [52] examined the safety of HBOT, also revealed 
that adverse events accompanying it were harmless and occurred 
infrequently. These results were reiterated in [47], which showed 
no significant variations in the frequency of harmful incidents 
between two groups.
Exceptionally, oxidative stress was reported as a potential 
risk associated with long-term HBOT [37], which stated that after 
20 sessions a significant elevation in oxidative stress parameters 
was noted in the HBOT group. Oxidative stress is defined as the 
condition of the imbalance between Reactive Oxygen Species 
(ROS) production and the capacity of a biological system to 
effectively remove or repair reactive intermediates [53]. The 
concern in the context of our topic is that the over-production of 
ROS, or the failure to detoxify this aggressive molecule, contributes 
to oxidative stress, an essential element in the pathogenesis of 
chronic, non-healing wounds. Most importantly, oxidative stress 
is the unavoidable by-product of the metabolism cycle, which can 
lead, if not inhibited, to apoptosis or necrosis in the large number 
of oxygen radicals which threaten all types of life [54]. Regardless 
of the pioneering work in considering this critical aspect [37], the 
limited sample size and the short length of that study hindered their 
results’ external validity. Moreover, it is suspected that increasing 
an HBOT dosage to two sessions a day was the cause for their 
results, which was contradictory to the intervention model utilised 
in the remaining studies. It is, however, a significant point that 
requires further study to obtain further compelling findings on 
HBOT’s oxidative stress impact.
Conclusion
Although HBOT has a long-standing history, it remains a 
controversial approach for treating diabetes-related foot ulcers. 
Therefore, our research investigated the effectiveness and safety 
of HBOT as a therapeutic intervention for DFUs. With respect to 
HBOT’s effectiveness, evidence has determined that HBOT is an 
intervention that has a positive influence on accelerating the healing 
of DFUs and decreasing their size, when used as an adjunctive 
therapy to standard wound care. The findings have also indicated 
the necessity of completing at least 20 sessions of HBOT—that is, 
reserving it for short-term use—to attain patient benefit. 
Nevertheless, the findings have also demonstrated that 
there is no added benefit of HBOT, when compared with standard 
treatment alone, in minimising the risk of minor or major 
amputations. Regarding the safety of HBOT, the findings confirm 
that the incidence of HBOT-related adverse effects is low. 
Additional large, multi-centre and well-designed trials to 
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rigorously evaluate the efficacy and safety of this intervention, 
particularly its relative effectiveness are required. 
Our study also recommends further studies to examine 
HBOT’s cost-effectiveness, in an effort to compare its clinical 
advantages to its expenses. Finally, studies that target physicians’ 
and nurses’ perceptions of HBOT’s effectiveness and patients that 
are eligible for its benefit are required.
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